Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This study is designed to provide long-term safety and efficacy data for the combination
doses of VAH (VAL/ HCTZ) 40/6.25mg and 80/12.5mg in essential hypertensive patients. The 350
patients (approximately) who have successfully finished the core trial CVAH631B1303 and
signed consent for the extension will be enrolled into this study.